Fresenius Medical Care: RBC maintains 'sector perform'
(CercleFinance.com) - RBC Capital Markets is maintaining its "sector perform" rating and 44 euro price target on Fresenius Medical Care, saying that the agreement to acquire NxStage Medical seems "strategically attractive.
"
The Canadian broker thinks the deal provides further vertical integration, while leveraging the kidney dialysis specialist's scale, and enhancing its growth trajectory.
RBC said it has slightly reduced its 2017 estimates for the German company following a "decent" set of second-quarter results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"
The Canadian broker thinks the deal provides further vertical integration, while leveraging the kidney dialysis specialist's scale, and enhancing its growth trajectory.
RBC said it has slightly reduced its 2017 estimates for the German company following a "decent" set of second-quarter results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.